Introduction {#s1}
============

Urinary tract infections (UTIs) are among the most common bacterial infections in humans, affecting 150 million people each year worldwide ([@bib14]). A high incidence of recurrence and frequent progression to chronic condition exacerbates the negative impact of UTIs on patients' quality of life and healthcare cost ([@bib16]). Despite the magnitude of the problem, treatment remains limited by a strain's susceptibility to available antibiotics, which are often ineffectual ([@bib1]; [@bib37]; [@bib43]).

The major causative agent of uncomplicated UTIs is Uropathogenic *Escherichia coli* (UPEC), which is responsible for upwards of 70% of all cases ([@bib14]). The majority of our insights into UPEC pathogenesis have been obtained through in vitro assays, cell culture systems, and animal models ([@bib3]; [@bib4]; [@bib45]; [@bib48]). While these studies have identified virulence and fitness factors that are important for UPEC infection, how these studies translate to human infection is not clear. As a result, we do not yet have a complete understanding of UPEC physiology in the human urinary tract. Moreover, the genetic heterogeneity of UPEC isolates, which carry diverse and functionally redundant virulence systems including iron acquisition, adherence, and toxins, further complicates our understanding of uropathogenesis ([@bib25]; [@bib26]; [@bib29]; [@bib40]; [@bib49]). The different constellations of virulence factors and diverse genetic backgrounds raise the question of whether different UPEC strains vary in their strategies for pathogenesis.

Since defining conserved UPEC characteristics have proven elusive to comparative genomics strategies, we hypothesized that comparing functional responses in the context of the host may uncover disease-defining features. To that end, we examined UPEC gene expression directly from 14 patients with documented significant bacteriuria and presenting with uncomplicated UTI and compared it to the gene expression of the identical strains cultured to mid-exponential stage in filter-sterilized pooled human urine. Despite the genetic diversity of the pathogen and the human hosts, we identified a remarkably conserved gene expression program that is specific to human infection and strongly supports previous findings of extremely rapid UPEC growth rate during UTI ([@bib8]; [@bib10]; [@bib15]). Importantly, we show that this transcriptional program is recapitulated in the mouse model of infection and propose a mechanism by which the fast growth rate can be achieved. Based on extensive analysis, we propose a model where UPEC shut down all non-essential metabolic processes and commit all available resources to rapid growth during human UTI. Critically, our discovery of a common transcriptional program of UPEC in patients significantly expands our understanding of bacterial adaptation to the human host and provides a platform to design universal therapeutic strategies.

Results {#s2}
=======

Study design {#s2-1}
------------

To better understand UPEC functional responses to the human host, we isolated and sequenced RNA from the urine (stabilized immediately after collection) from fourteen otherwise healthy women diagnosed with UPEC-associated urinary tract infection. To identify infection-specific responses, we cultured the same fourteen UPEC isolates in vitro in filter-sterilized human urine (mid-exponential phase, 2 hr time point in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}), and isolated and sequenced RNA from these cultures (study design and quality control is described in detail in Methods section). Phylogenetic analysis showed a high degree of genetic diversity, as we identified strains belonging to three distinct phylogroups, 13 different sequence types, and 13 distinct serogroups ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}, [Table 1](#table1){ref-type="table"}, [Table 2](#table2){ref-type="table"}). The majority of UPEC isolates (10 of 14) belonged to the B2 phylogroup, which is consistent with previously published studies ([@bib16]; [@bib40]). Although the majority (10 of 14) of patients had a previous history of UTIs, we found no relationship between patients' previous UTI history and bacterial genotype ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Moreover, the 14 clinical isolates showed a wide array of antibiotic resistance phenotypes ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}).
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###### Sequence type for 14 clinical UPEC isolates

  Strain   Sequence type   *Adk*   *fumC*   *gyrB*   *Icd*   *Mdh*   *purA*   *recA*
  -------- --------------- ------- -------- -------- ------- ------- -------- --------
  HM01     69              21      35       27       6       5       5        4
  HM03     101             43      41       15       18      11      7        6
  HM06     131             53      40       47       13      36      28       29
  HM07     641\*           9       6        33\*     131     24      8        7
  HM14     Novel           6       4        4        16      24      13       14
  HM17     73              36      24       9        13      17      11       25
  HM43     Novel\*         40\*    14       19       36      17      10       203
  HM54     404\*           14\*    14       10       14      17      7        74
  HM56     538             13      40       19       13      36      28       30
  HM57     73              36      24       9        13      17      11       25
  HM60     648             92      4        87       96      70      58       2
  HM66     80              13      24       19       14      23      1        10
  HM68     998             13      52       156      14      17      25       17
  HM86     127             13      14       19       36      23      11       10
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###### In silico determined serotypes for 14 clinical UPEC strains

  Strain   H_type   O_type
  -------- -------- ----------
  HM01     H4       O25
  HM03     H21      NA
  HM06     H4       O25
  HM07     H45      O45
  HM14     H10      O8
  HM17     H1       O6
  HM43     H23      NA
  HM54     H5       O75
  HM56     H4       O13/O135
  HM57     H1       O2/O50
  HM60     H10      O102
  HM66     H7       O7
  HM68     H6       O2/O50
  HM86     H31      O6

Virulence factor expression is observed both during urine culture and human infection {#s2-2}
-------------------------------------------------------------------------------------

We first assessed the virulence genotype of the fourteen UPEC strains by looking at the presence or absence of a comprehensive list of known virulence factors, including adhesins, toxins, iron acquisition proteins, and flagella ([@bib26]; [@bib27]; [@bib29]; [@bib40]; [@bib48]; [@bib50]) ([Figure 1A](#fig1){ref-type="fig"}). As previously reported ([@bib40]), B1 strains appear to carry fewer virulence factors overall when compared to B2 strains, suggesting that UTIs can be established by UPEC strains with vastly diverse virulence genotypes. We then compared the levels of gene expression of these virulence factors following culture in filter-sterilized urine ([Figure 1B](#fig1){ref-type="fig"}, [Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}) to that during infection. As expected, we detected expression of genes involved in iron acquisition during both in vitro urine culture and human UTI ([Figure 1B](#fig1){ref-type="fig"}). However, we also observed high strain-to-strain variability in gene expression, especially for *hma, iutA, iucC and fyuA*, which is consistent with previous reports ([@bib47]).

![Clinical UPEC isolates carry a highly variable set of virulence factors.\
Phenotypic and genotypic information about the strains can be found in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}, [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}, [Table 1](#table1){ref-type="table"}, and [Table 2](#table2){ref-type="table"}. (**A**) Clinical UPEC isolates were examined for presence of 40 virulence factors. Virulence factors were identified based on homology using BLAST searches (≥80% identity,≥90% coverage). The heatmap shows presence (black) or absence (white) of virulence factors across 14 UPEC strains. Hierarchical clustering based on presence/absence of virulence factors shows separate clustering of B1 isolates. (**B**) Log~2~ TPM for iron acquisition genes (top panel) and adhesins (bottom panel) in urine and patient samples. Gene expression of other virulence factors is shown in [Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}. Correlations of virulence factor expression among in vitro and patient samples is shown in [Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}. (**C**) Log~2~ TPM of *fim* (top panel) and *flg* (bottom panel) operons across the 14 UPEC strains during in vitro urine culture and human UTI.](elife-49748-fig1){#fig1}

Most of the adhesin genes were expressed at very low levels both during in vitro culture and infection, with the exception of *fim* genes ([Figure 1B](#fig1){ref-type="fig"}). Interestingly, we observed high variability in *fim* and *flg* operon expression between patients ([Figure 1C](#fig1){ref-type="fig"}). In the majority of the cases, we detected high levels of *fim* operon expression (9/14) and low levels of *flg* operon expression (12/14). However, in the sample collected from patient HM07, we observed high levels of both *fim* and *flg* expression, potentially indicating a mixed population of both motile and adherent bacteria present in the sample. Overall, the variability in the expression of adhesin and motility machinery might suggest different stages of infection.

Other virulence factors examined were expressed at either similar or lower levels during human UTI compared to in vitro urine cultures ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). Notably, virulence factor carriage varies greatly between UPEC strains and we did not discern any infection-specific gene expression among the virulence factors we examined ([Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}).

The UPEC core genome exhibits a common gene expression program during clinical infection {#s2-3}
----------------------------------------------------------------------------------------

Since patient samples contained fewer bacterial reads compared to in vitro controls, we first performed a rigorous quality assurance analysis, which indicated that we possessed sufficient sequencing depth for downstream analyses ([Table 3](#table3){ref-type="table"}, [Table 4](#table4){ref-type="table"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}, [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}, see Materials and methods for details). Next, to perform a comprehensive comparison of gene expression between the different clinical UPEC strains, we identified a set of 2653 genes present in all 14 UPEC strains in this study as well as the reference *E. coli* MG1655 strain (hereafter referred to as the core genome). We then compared the gene expression correlation of the core genome to that of the accessory genome (*i.e*., 2219 genes that were present in at least two but not all of the clinical UPEC strains) for all 14 isolates cultured in vitro in filter-sterilized urine. As expected for bacterial strains cultured under identical conditions, we saw high correlation of gene expression between any two isolates cultured in vitro irrespective of whether these genes were part of the core or accessory genome ([Figure 2A](#fig2){ref-type="fig"}). Remarkably, we also observed a high degree of gene expression correlation for the core genome, but not the accessory genome, across all 14 patient samples ([Figure 2B](#fig2){ref-type="fig"}). This suggested the expression of core genes is conserved during human UTI, while expression of accessory genome might be more reflective of the specific conditions during each infection. Furthermore, the gene expression correlation within urine samples ([Figure 2C](#fig2){ref-type="fig"}, [Figure 2D](#fig2){ref-type="fig"}, median correlation 0.92, URINE:URINE), and within patient samples ([Figure 2C](#fig2){ref-type="fig"}, [Figure 2D](#fig2){ref-type="fig"}, median correlation 0.91, PATIENT:PATIENT) was considerably higher than the gene expression correlation between in vitro urine and patient samples ([Figure 2C](#fig2){ref-type="fig"}, [Figure 2D](#fig2){ref-type="fig"}, median correlation 0.73, URINE:PATIENT). The gene expression correlation between in vitro and patient samples remained low, even when we directly compared identical strains (*i.e.* HM56 cultured in vitro in urine vs. HM56 isolated from the patient) ([Figure 2C](#fig2){ref-type="fig"}, [Figure 2D](#fig2){ref-type="fig"}, median of 0.74, URINE:PATIENT:matched). This analysis suggested that UPEC adopt an infection-specific gene expression program that is distinct from UPEC undergoing exponential growth in urine in vitro. Finally, we independently confirmed this observation using principal component analysis (PCA), which revealed that patient samples form a tight cluster, distinct from in vitro cultures ([Figure 2E](#fig2){ref-type="fig"}), demonstrating the common transcriptional state of UPEC during human UTI.
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###### Summary of alignment statistics (% mapped).

  -------------------------------------------------------------------------------------------------------------------------------
  Sample:       Total\      Mapped\    \% Mapped   \% Mapped\   \% Mapped\    \% Mapped\   \% Mapped\   \% Mapped\   \% Mapped\
                reads       reads                  to CDS       to misc_RNA   to rRNA      to tRNA      to sRNA      to tmRNA
  ------------- ----------- ---------- ----------- ------------ ------------- ------------ ------------ ------------ ------------
  HM01 \| UR    17288419    16480326   95.3        74.91        5.51          0.01         0.26         10.2         5.49

  HM01 \| UTI   18496607    3717040    20.1        80.44        3.36          0            0.51         3.42         2.45

  HM03 \| UR    21354719    20927541   98          77.77        4.78          0            0.36         9.49         5.21

  HM03 \| UTI   16544044    8059076    48.7        80.18        2.45          0            0.86         2.23         1.35

  HM06 \| UR    23359847    22847374   97.8        78.72        3.96          0            0.33         6.3          3.23

  HM06 \| UTI   57993519    4709092    8.1         76.94        2.62          0            0.36         1.55         0.87

  HM07 \| UR    21312224    20980473   98.4        75.2         6.02          0            0.19         10.32        4.79

  HM07 \| UTI   70804688    2097350    3           73.71        4.14          0            0.6          2.08         0.77

  HM14 \| UR    21927302    21533817   98.2        76.13        5.33          0            0.15         9.97         5.16

  HM14 \| UTI   15944762    12968218   81.3        80.51        2.21          0            0.46         2.25         1.5

  HM17 \| UR    19790215    19360294   97.8        77.41        4.29          0            0.13         7.02         3.32

  HM17 \| UTI   23874585    1842583    7.7         74.35        4.14          0            0.73         2.73         1.6

  HM43 \| UR    18541484    18239826   98.4        76.54        5.03          0            0.21         9.07         4.76

  HM43 \| UTI   58306859    8138559    14          80.38        2.76          0            0.37         3.95         2.38

  HM54 \| UR    21612581    21162544   97.9        74.96        4.13          0.01         0.12         7.17         4.06

  HM54 \| UTI   18000843    6301998    35          77.33        3.05          0.01         0.52         1.54         0.98

  HM56 \| UR    17494135    17130847   97.9        77.93        4.09          0            0.09         7.14         3.56

  HM56 \| UTI   25408755    14935948   58.8        79.41        2.59          0            0.58         1.98         1.17

  HM57 \| UR    19253078    18966748   98.5        77.07        4.85          0            0.08         8.26         3.86

  HM57 \| UTI   105629816   926795     0.9         71.48        4.2           0            0.65         2.63         1.5

  HM60 \| UR    15898045    15651916   98.5        76.35        4.14          0            0.09         7.47         4.05

  HM60 \| UTI   76149837    764255     1           70.69        3.76          0            0.7          1.84         1.04

  HM66 \| UR    17184018    16736066   97.4        74.15        4.93          0            0.12         9.53         5.28

  HM66 \| UTI   25954183    79859      0.3         65.41        2.71          0            0.46         1.42         0.67

  HM68 \| UR    15841639    15562711   98.2        78.31        2.84          0            0.14         6.03         3.67

  HM68 \| UTI   65413931    2401089    3.7         73.11        4.8           0            0.83         4.58         2.73

  HM86 \| UR    15019669    14606346   97.2        76.06        4.09          0            0.16         6.99         3.54

  HM86 \| UTI   10667404    6413794    60.1        78.33        2.8           0            0.77         3.08         1.62
  -------------------------------------------------------------------------------------------------------------------------------
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###### Summary of alignment statistics (raw counts).

  Sample:       CDS        misc_RNA   rRNA   tRNA    sRNA      tmRNA
  ------------- ---------- ---------- ------ ------- --------- ---------
  HM01 \| UR    12345933   907900     1504   43435   1680592   905367
  HM01 \| UTI   2989889    124744     143    19133   126985    91056
  HM03 \| UR    16274560   999727     44     76181   1985885   1090263
  HM03 \| UTI   6461781    197433     24     69006   179905    109081
  HM06 \| UR    17985174   904287     43     76160   1439268   738927
  HM06 \| UTI   3623181    123428     23     17015   72873     40864
  HM07 \| UR    15776986   1262236    177    39363   2165537   1005391
  HM07 \| UTI   1546060    86761      30     12681   43708     16065
  HM14 \| UR    16393471   1148443    86     32625   2146180   1110769
  HM14 \| UTI   10441062   286490     50     59823   291189    194198
  HM17 \| UR    14986237   830647     48     24865   1358261   642452
  HM17 \| UTI   1370047    76227      15     13494   50273     29443
  HM43 \| UR    13960276   916836     21     37450   1653607   867656
  HM43 \| UTI   6541810    225003     29     30200   321597    194030
  HM54 \| UR    15863933   873414     1662   25326   1517844   858505
  HM54 \| UTI   4873058    192289     353    32932   97321     61939
  HM56 \| UR    13349576   701313     78     15697   1222601   609922
  HM56 \| UTI   11860835   386845     52     86723   295607    175048
  HM57 \| UR    14617905   919256     157    15069   1567276   732845
  HM57 \| UTI   662515     38910      13     6057    24340     13929
  HM60 \| UR    11949731   647306     62     13601   1169464   633959
  HM60 \| UTI   540215     28718      11     5361    14062     7958
  HM66 \| UR    12409693   825583     51     19323   1595303   884439
  HM66 \| UTI   52232      2161       0      366     1137      534
  HM68 \| UR    12187024   442312     22     22226   938831    571220
  HM68 \| UTI   1755457    115276     16     19970   110052    65627
  HM86 \| UR    11110009   597368     551    23424   1021292   517105
  HM86 \| UTI   5023803    179823     46     49276   197828    103919

![Core genome expression in patients is highly correlated.\
The analysis details are described in Materials and methods, and figure supplements. (**A**)-(**B**) Histogram of Pearson correlation coefficients among all samples cultured in vitro (**A**) or isolated from patients (**B**) based either on core genome or accessory genome comparisons. Accessory genome includes genes that were found in at least two but fewer than 14 of the clinical isolates. (**C**) Correlations among in vitro and patient samples measured by Pearson correlation coefficient of normalized gene expression plotted according to hierarchical clustering of samples. (**D**) Pearson correlation coefficient among all samples cultured in vitro (URINE \| URINE, median = 0.92), among all samples isolated from patients (PATIENT \| PATIENT, median = 0.91), between samples cultured in urine and samples isolated from patients (URINE \| PATIENT, median = 0.73), and between matching urine/patient samples (ex. HM14 \| URINE vs HM14 \| PATIENT), (URINE \| PATIENT:matched, median = 0.74). (**E**) Principal component analysis of normalized gene expression of 14 clinical isolates in patients and in vitro urine cultures shows distinct clustering of in vitro and patient isolates.\
10.7554/eLife.49748.014Figure 2---source data 1.Genes differentially expressed between B1 and B2 phylogroup strains during in vitroculture in urine.\
10.7554/eLife.49748.015Figure 2---source data 2.Genes differentially expressed between B1 and B2 phylogroup strains during human UTI.](elife-49748-fig2){#fig2}

We also performed PCA analysis on in vitro ([Figure 2---figure supplement 3A,B](#fig2s3){ref-type="fig"}) and patient samples ([Figure 2---figure supplement 3C,D](#fig2s3){ref-type="fig"}) separately, to ascertain whether there was any discernible effect of bacterial phylogroup ([Figure 2---figure supplement 3A,C](#fig2s3){ref-type="fig"}) or patients' previous history of UTI ([Figure 2---figure supplement 3B,D](#fig2s3){ref-type="fig"}) on gene expression. Interestingly, B1 and B2 strains did cluster separately and a number of genes were expressed differentially in B1 and B2 backgrounds ([Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}, [Figure 2---source data 2](#fig2sdata2){ref-type="supplementary-material"}), suggesting that variation in gene regulatory elements between phylogroups has a small but discernible role in gene expression both in vitro and during infection. However, we found that patients' history of UTI had no effect on bacterial gene expression.

Taken together, our data indicate diverse UPEC strains adopt a specific and conserved transcriptional program for their core genes during human infection.

UPEC show increased expression of replication and translation machinery during UTI {#s2-4}
----------------------------------------------------------------------------------

Differential expression analysis of the infection and in vitro transcriptomes identified 492 differentially expressed genes (log~2~ fold change greater than two or less than −2, adjusted *p* values \< 0.05) ([Figure 3A](#fig3){ref-type="fig"}, [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}, [Figure 3---source data 2](#fig3sdata2){ref-type="supplementary-material"}). Interestingly, pathway analysis ([Table 5](#table5){ref-type="table"}) and manual curation of the differentially expressed gene list ([Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}) revealed that expression of ribosomal subunits (r-proteins), and enzymes involved in rRNA, tRNA modification, purine and pyrimidine metabolism, and ribosome biogenesis are significantly higher in patients compared to in vitro cultures ([Figure 3B](#fig3){ref-type="fig"}). Together with previous studies ([@bib8]; [@bib10]; [@bib15]), these data strongly suggest that replication rates during infection are significantly higher than during mid-exponential growth in urine in vitro.

![Patient-associated transcriptional signature is consistent with rapid bacterial growth.\
(**A**) The DESeq2 R package was used to compare in vitro urine cultures gene expression to that in patients. Each UPEC strain was considered an independent replicate (n = 14). Genes were considered up-regulated (down-regulated) if log~2~ fold change in expression was higher (lower) than 2 (vertical lines), and *P* value \< 0.05 (horizontal line). Using these cutoffs, we identified 149 upregulated genes, and 343 downregulated genes. GO/pathway analysis showed that a large proportion of these genes belonged to one of the four functional categories (see legend). For each category, only the genes that have met the significance cut off are shown. The sugar transporters upregulated in UTI patients are shown in figure supplement. (**B**) Mean normalized expression for genes belonging to differentially expressed functional categories/pathways. The number of up or down-regulated genes belonging to each category is indicated next to the category name.\
10.7554/eLife.49748.021Figure 3---source data 1.Genes upregulated during human UTI.\
10.7554/eLife.49748.022Figure 3---source data 2.Genes downregulated during human UTI.](elife-49748-fig3){#fig3}
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###### GO modules differentially expressed in UTI patients.

  Go id        Annotated   Significant   Expected   P value   Term
  ------------ ----------- ------------- ---------- --------- ---------------------------------------------------------------
  GO:0006518   89          24            16.63      0.03134   peptide metabolic process
  GO:0016052   76          36            14.2       0.00403   carbohydrate catabolic process
  GO:0044262   75          29            14.01      0.0022    cellular carbohydrate metabolic process
  GO:0015980   70          20            13.08      0.02632   energy derivation by oxidation of organic compounds
  GO:0043043   69          19            12.89      0.04306   peptide biosynthetic process
  GO:0046395   65          25            12.14      0.00556   carboxylic acid catabolic process
  GO:0006412   63          18            11.77      0.03421   translation
  GO:0008643   55          30            10.28      0.02488   carbohydrate transport
  GO:1903825   39          12            7.29       0.04583   organic acid transmembrane transport
  GO:0008033   38          13            7.1        0.0159    tRNA processing
  GO:1905039   38          12            7.1        0.03786   carboxylic acid transmembrane transport
  GO:0046365   38          21            7.1        0.04177   monosaccharide catabolic process
  GO:0034219   37          20            6.91       0.0005    carbohydrate transmembrane transport
  GO:0042710   35          11            6.54       0.04746   biofilm formation
  GO:0044010   34          11            6.35       0.03879   single-species biofilm formation
  GO:0006400   34          11            6.35       0.03879   tRNA modification
  GO:0072329   32          15            5.98       0.02795   monocarboxylic acid catabolic process
  GO:0009401   30          11            5.6        0.01501   phosphoenolpyruvate-dependent sugar phosphotransferase system
  GO:0010608   29          10            5.42       0.03121   posttranscriptional regulation of gene expression
  GO:0034248   26          9             4.86       0.03925   regulation of cellular amide metabolic process
  GO:0006417   26          9             4.86       0.03925   regulation of translation
  GO:0015749   24          13            4.48       0.03338   monosaccharide transmembrane transport
  GO:0051248   23          9             4.3        0.01728   negative regulation of protein metabolic process
  GO:0044275   22          11            4.11       0.04263   cellular carbohydrate catabolic process
  GO:0032269   22          8             4.11       0.03829   negative regulation of cellular protein metabolic process
  GO:0015807   19          7             3.55       0.04819   L-amino acid transport
  GO:0017148   18          8             3.36       0.01044   negative regulation of translation
  GO:0034249   18          8             3.36       0.01044   negative regulation of cellular amide metabolic process
  GO:1902475   17          7             3.18       0.02607   L-alpha-amino acid transmembrane transport
  GO:0009409   14          8             2.62       0.00144   response to cold
  GO:0042255   14          9             2.62       0.00021   ribosome assembly
  GO:0019321   14          8             2.62       0.03705   pentose metabolic process
  GO:0046835   13          6             2.43       0.02143   carbohydrate phosphorylation
  GO:0006526   12          8             2.24       0.00034   arginine biosynthetic process
  GO:0042542   10          5             1.87       0.02449   response to hydrogen peroxide
  GO:0019323   10          7             1.87       0.02539   pentose catabolic process

We also observed infection-specific downregulation of pathways involved in amino acid biosynthesis and sugar metabolism, and a general switch from expression of sugar transporters to that of amino acid transporters ([Figure 3B](#fig3){ref-type="fig"}, [Figure 3---source data 2](#fig3sdata2){ref-type="supplementary-material"}) (with the exception of 4 sugar transporters that were expressed at higher levels in patients: *ptsG*, *fruA*, *fruB*, and *gntU*. [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Downregulation of sugar catabolism genes and upregulation of amino acid transporters suggest a metabolic switch to a more specific catabolic program as well as a scavenger lifestyle as elaborated below.

A shift in metabolic gene expression during UTI to optimize growth potential {#s2-5}
----------------------------------------------------------------------------

During our analysis, we observed that 99% (on average 2621/2653 genes) of core genome was expressed during in vitro culture, in contrast to only 94% in patient samples (2507/2653 genes). Patient samples also contained higher proportion of genes expressed at low levels when compared to in vitro samples. ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). Moreover, we noted that the majority of differentially expressed genes were downregulated in patients (343/492 differentially expressed genes). On the other hand, 30% of all upregulated genes (48/149) were ribosomal proteins. Together, these data gave us the first indication that UPEC may undergo a global gene expression reprogramming during urinary tract infection.

Bacterial growth laws postulate that bacteria dedicate a fixed amount of cellular resources to the expression of ribosomes and metabolic machinery. As a consequence, higher growth rates are achieved by allocating resources to ribosome expression at the expense of metabolic machinery production ([@bib7]; [@bib6]; [@bib36]; [@bib41]; [@bib42]; [@bib52]). However, this resource reallocation between ribosomal and metabolic gene expression has not yet been measured in vivo.

First, we wanted to determine what proportion of the total transcriptome is dedicated to core genome expression. We hypothesized that during infection transcription could shift from the core genome to the accessory genome, which is enriched for virulence factors. However, we found that approximately 50% of total reads mapped to the core genome regardless of whether the bacteria were isolated from the patients or cultured in vitro ([Figure 4A](#fig4){ref-type="fig"}). Therefore, our data indicated that a fixed proportion of cellular resources were being dedicated to expression of conserved ribosomal and metabolic machinery, regardless of external environment.

![UPEC optimize growth potential via resource reallocation during UTI.\
(**A**) Percentage of reads that aligned to the core genome (2653 genes) out of total mapped reads. (**B**) Percentage of core genome reads that mapped to r-proteins (ribosomal subunit proteins, 48 genes). (**C**) Percentage of core genome reads that mapped to catabolic genes (defined as genes regulated by Crp and present in the core genome (277 genes). (**D**) Percentage of core genome reads that mapped to amino acid biosynthesis genes (54 genes). The equivalent analysis of [@bib47] dataset is shown in the figure supplement.](elife-49748-fig4){#fig4}

We next looked at r-protein expression. Remarkably, we found that almost 25% of core genome reads mapped to r-proteins during infection, while this number was only 7% during exponential growth in urine ([Figure 4B](#fig4){ref-type="fig"}). These findings support the idea of extremely fast UPEC growth during UTI. Furthermore, this increase in r-protein expression correlated with a marked decrease in the proportion of core genome reads dedicated to the expression of catabolic genes (20% in vitro, 11% in patients, [Figure 4C](#fig4){ref-type="fig"}) and amino acid biosynthesis genes (5% in vitro, 1% in patients, [Figure 4D](#fig4){ref-type="fig"}). We then performed the same analysis on our previously published dataset ([@bib47]), and found a consistent trend of increased r-protein production, and decreased catabolic enzyme expression during human UTI ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}, [Table 6](#table6){ref-type="table"}, [Table 7](#table7){ref-type="table"}). Thus, our data, which are consistent across multiple data sets, highlight a dramatic and conserved resource reallocation from metabolic gene expression to replication and translational gene expression during human UTI. We postulate that this resource reallocation is required to facilitate the rapid growth rate of UPEC in the host, which has been previously documented ([@bib10]; [@bib15]).

10.7554/eLife.49748.025

###### Summary of alignment statistics (% mapped) for [@bib47].

  -------------------------------------------------------------------------------------------------------
  Sample:       Total       Mapped\     \% Mapped   Mapped\   Mapped to\   Mapped\   Mapped\   Mapped\
                            reads                   to CDS    misc_RNA     to rRNA   to tRNA   to tmRNA
  ------------- ----------- ----------- ----------- --------- ------------ --------- --------- ----------
  HM46 \| UR    84195438    81447525    96.74       2.41      0.05         60.55     0.01      0.01

  HM26 \| UTI   20253252    1000968     4.94        16.75     0.24         21.24     0.09      0.16

  HM46 \| UTI   63338418    10783798    17.03       6.93      0.12         40.3      0.1       0.1

  HM27 \| LB    67422498    65065615    96.5        2.25      0.04         55.6      0.02      0.01

  HM27 \| UTI   67258748    18308171    27.22       9.25      0.13         45.49     0.08      0.2

  HM26 \| UR    62242978    59994538    96.39       2.31      0.08         60.58     0.01      0.01

  HM65 \| LB    73451346    71221338    96.96       2.53      0            51.41     0.01      0

  HM69 \| LB    137690758   133649727   97.07       3.49      0.05         67.26     0.01      0.01

  HM69 \| UTI   72509214    38506559    53.11       6.52      0.13         42.09     0.04      0.21

  HM46 \| LB    78018026    75590297    96.89       2.78      0.06         56.9      0.01      0.01

  HM27 \| UR    98185180    94683534    96.43       2.82      0.03         61        0.01      0.01

  HM26 \| LB    70919896    68671798    96.83       2.02      0.06         55.74     0.02      0.01

  HM65 \| UR    76024008    73555939    96.75       2.49      0            55.04     0.01      0

  HM65 \| UTI   73446576    59696718    81.28       6.19      0            40.3      0.04      0

  HM69 \| UR    67112750    64834311    96.61       2.45      0.04         52.92     0.01      0.01
  -------------------------------------------------------------------------------------------------------
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###### Summary of alignment statistics (% mapped) for [@bib47].

  Sample        CDS       misc_RNA   rRNA       tRNA    tmRNA
  ------------- --------- ---------- ---------- ------- -------
  HM46 \| UR    1960841   36901      49312604   7302    5604
  HM26 \| UTI   167663    2366       212641     949     1605
  HM46 \| UTI   747702    12948      4345881    10289   11281
  HM27 \| LB    1463627   26081      36173268   11717   5088
  HM27 \| UTI   1693448   24245      8329004    14427   36287
  HM26 \| UR    1387110   48847      36345620   6532    5837
  HM65 \| LB    1801858   0          36612190   7263    1
  HM69 \| LB    4664579   71881      89896218   13828   7949
  HM69 \| UTI   2511733   51962      16206680   17070   81355
  HM46 \| LB    2099493   42356      43011663   11135   8549
  HM27 \| UR    2673283   31185      57757240   10152   8399
  HM26 \| LB    1385766   38971      38278745   11081   5724
  HM65 \| UR    1828039   0          40486611   5675    1
  HM65 \| UTI   3697360   0          24059705   24055   2
  HM69 \| UR    1587484   26322      34308170   4737    7686

Increase in r-protein transcripts is an infection-specific response {#s2-6}
-------------------------------------------------------------------

Doubling time during exponential growth in urine is longer than the doubling time during exponential growth in rich media, such as LB ([@bib39]). Thus, we wanted to determine whether the differences between the infection-specific and in vitro transcriptomes are due to longer doubling times of UPEC cultured in urine. For that purpose, one of the clinical strains, HM43, was cultured in LB, and in a new batch of filter sterilized urine. Using the growth curves shown in [Figure 5A](#fig5){ref-type="fig"}, we estimated the doubling time of HM43 during exponential growth in LB to be approximately 33 min and the doubling time in urine to be 54 min. In addition, we sequenced RNA from 3-hour-old LB cultures, 3-hour-old urine cultures and from the urine of CBA/J mice, 48 hr after transurethral inoculation with HM43 ([Table 8](#table8){ref-type="table"}, [Table 9](#table9){ref-type="table"}).
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###### Summary of alignment statistics (% mapped) for mouse UTI study.

  ----------------------------------------------------------------------------------------------------------------------
  Sample               Total\     Mapped\    \% Mapped   Mapped\   Mapped to\   Mapped\   Mapped\   Mapped\   Mapped\
                       reads      reads                  to CDS    misc_RNA     to rRNA   to tRNA   to sRNA   to tmRNA
  -------------------- ---------- ---------- ----------- --------- ------------ --------- --------- --------- ----------
  HM43 \| LB \| rep1   63966646   62813946   98.2        73.01     5.49         0         0.2       11.03     6.41

  HM43 \| LB \| rep2   37833957   37090863   98.04       71.59     5.91         0         0.2       11.63     6.69

  HM43 \| UR \| rep1   43179946   42293006   97.95       63        8.9          0         0.06      19.96     11.94

  HM43 \| UR \| rep2   44176952   43093840   97.55       53.64     10.94        0.01      0.03      27.8      17.9

  HM43 \| mouse        44314537   3690174    8.33        76.72     2.75         0         0.24      6.11      4
  ----------------------------------------------------------------------------------------------------------------------
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###### Summary of alignment statistics (% mapped) for mouse UTI study.

  Sample               CDS        misc_RNA   rRNA   tRNA     sRNA       tmRNA
  -------------------- ---------- ---------- ------ -------- ---------- ---------
  HM43 \| LB \| rep1   45862961   3449232    327    123950   6929261    4028787
  HM43 \| LB \| rep2   26554546   2192539    204    74396    4312075    2482416
  HM43 \| UR \| rep1   26644071   3765281    218    26488    8439668    5049595
  HM43 \| UR \| rep2   23115456   4714597    2962   14049    11979913   7714978
  HM43 \| mouse        2831120    101419     55     8994     225533     147467

![Increased expression of ribosomal subunit transcripts is a host specific response.\
(**A**) Growth curve for HM43 strain cultured in LB and filter-sterilized urine. (**B**) Percentage of HM43 core genome reads that mapped to ribosomal subunit proteins under different conditions (URINE: in vitro culture in filter-sterilized urine, LB: in vitro culture in LB, MOUSE: mice with UTI, PATIENT: human UTI. (**C**) Percentage of HM43 core genome reads that mapped to catabolic genes under different conditions.](elife-49748-fig5){#fig5}

We then determined the proportion of r-protein transcripts in the HM43 transcriptomes isolated from urine and LB cultures. Consistent with our previous experiments, this proportion was very small in urine culture (4%). Interestingly, while the proportion of r-protein transcripts was approximately three times larger in LB cultures compared to urine, it was still significantly lower compared to what we observed during infection ([Figure 5B](#fig5){ref-type="fig"}). In contrast, the bacterial transcriptome during mouse infection exhibited r-protein expression that was similar to the human infection ([Figure 5B](#fig5){ref-type="fig"}). Additionally, the proportion of the transcriptome dedicated to catabolic gene expression was highest during urine cultures and lowest during mouse and human infections, indicating a negative correlation between the expression of r-protein and sugar catabolism genes. ([Figure 5C](#fig5){ref-type="fig"}). Overall, we show that exponential growth in rich medium alone cannot recapitulate the transcriptional signature observed during human infection. Taken together, our data suggest that the resource reallocation described in this study is an infection-specific response.

Environment-responsive regulators facilitate patient-specific gene expression program {#s2-7}
-------------------------------------------------------------------------------------

We next sought to identify potential regulators involved in resource reallocation that facilitate the infection-specific UPEC gene expression program. To do so, we performed gene set enrichment analysis (GSEA) on *E. coli* co-regulated genes (regulons). This analysis allowed us to identify regulons enriched in differentially expressed genes. We identified 22 transcriptional factors whose regulon's expression was statistically different between infection and in vitro cultures ([Table 10](#table10){ref-type="table"}). 18/22 regulons were expressed at higher level during in vitro culture, and eight representative regulons are shown in [Figure 6](#fig6){ref-type="fig"}. Overall, we found that these regulons accounted for 50% of differentially expressed genes that were determined to be significantly down-regulated. In contrast, only 6% of upregulated genes belonged to the four regulons that were expressed at higher levels during infection. These included genes involved in the SOS response, as well as purine synthesis ([Table 10](#table10){ref-type="table"}).
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###### GSEA results.

Gene sets found to be enriched in differentially expressed genes. For example, Lrp, Repressor indicates gene set repressed by Lrp (data obtained from RegulonDB 9.4). Expression indicates whether regulon expression was higher in patients of during in vitro culture in urine. Regulon size: number of genes in the gene set; Matched size: number of genes found in data set; NES: normalized enrichment score; FDR: false discovery rate.

  ----------------------------------------------------------------------------------------
         Function    Expression\   Regulon size   Matched size   NES          FDR
                     (higher in)                                              
  ------ ----------- ------------- -------------- -------------- ------------ ------------
  Lrp    Repressor   Urine         85             27             2.29079978   0

  NarL   Repressor   Urine         87             65             2.24435801   0

  Lrp    Activator   Urine         38             19             2.21269565   0

  MetJ   Repressor   Urine         15             14             2.12885223   0.00083422

  Crp    Activator   Urine         425            277            2.12150402   0.00066738

  CsgD   Activator   Urine         13             12             2.01197693   0.00250267

  GadX   Activator   Urine         23             15             1.89350304   0.00929563

  ModE   Activator   Urine         31             28             1.87289606   0.0108449

  YdeO   Activator   Urine         18             14             1.81975146   0.02002136

  Fur    Repressor   Urine         110            66             1.76658693   0.02752936

  PhoP   Activator   Urine         45             33             1.7607379    0.0256334

  RcsB   Activator   Urine         58             28             1.70667558   0.03781812

  Hns    Repressor   Urine         144            62             1.69880665   0.03657748

  GadE   Activator   Urine         70             38             1.69400478   0.03515655

  RcsA   Activator   Urine         42             24             1.68615633   0.03448122

  NarP   Activator   Urine         32             29             1.65675898   0.04045982

  NarP   Repressor   Urine         33             26             1.6406359    0.04279074

  FhlA   Activator   Urine         30             15             1.62536048   0.04514074

  FliZ   Repressor   Urine         20             15             1.60948953   0.04750681

  LexA   Repressor   Patients      59             43             −1.696072    0.03586007

  Cra    Repressor   Patients      59             50             −1.7121855   0.04267527

  PurR   Repressor   Patients      31             31             −1.752299    0.04410253

  FadR   Activator   Patients      12             11             −1.9871524   0.00342544
  ----------------------------------------------------------------------------------------

![Differential regulon expression suggests role for multiple regulators in resource reallocation.\
Regulon expression for 8 out of 22 regulons enriched for genes downregulated in the patients. Expression of each gene in the regulon during in vitro culture (blue) or during UTI (red) is shown along the x-axis. Histograms show proportion of genes in the regulon expressed at any given level.](elife-49748-fig6){#fig6}

In support of our previous data, the expression of catabolic genes controlled by the Crp regulator was lower in patients compared to urine cultures. In conjunction with the previously described role for Crp in resource reallocation ([@bib52]), our in vivo findings strongly suggest that catabolite repression plays an important role in bacterial growth rate during UTI. Interestingly, other regulators identified in this analysis (NarL, ModE, MetJ, GadE, YdeO) are known sensors of environmental cues, suggesting that the infection-specific gene expression program may be driven by additional environmental signals. Taken together, we propose a model where simultaneous sensing of multiple environmental cues in the urinary tract leads to the global down-regulation of multiple metabolic regulons during infection. The cellular resources (*e.g*., RNA polymerase) that are freed as a result are then allocated to the transcription of genes (for example, r-proteins), which are required to maintain rapid growth rate.

Discussion {#s3}
==========

UPEC causes one of the most prevalent bacterial infections in humans; consequently, the virulence mechanisms of UPEC infection have been well-characterized. However, while we know that these virulence strategies (*e.g.*, iron acquisition, adhesion, immune evasion) are essential for establishing infection, UPEC strains can differ dramatically in the specific factors that are utilized. Additionally, our data indicate that the expression of virulence factors can change from patient to patient, suggesting that the need for a specific factor might vary during the course of the infection.

In this study, we set out to uncover universal bacterial features during human UTIs, regardless of the stage of the infection or patient history. To do so, we performed transcriptomic analysis on bacterial RNA isolated directly from the urine of 14 patients and compared it to the gene expression of identical strains cultured to mid-exponential phase in sterile urine. Our analysis focused on the core genome as opposed to the more commonly studied accessory genome, which contains the majority of the classical virulence factors. This allowed us to identify a remarkably conserved gene expression signature shared by all 14 UPEC strains during UTI.

Although frequently overlooked, bacterial metabolism is an essential component of bacterial pathogenesis. Since the core genome is enriched for metabolic genes, we anticipated that our study would illuminate the UPEC metabolic state during human infection. Our data revealed an infection-specific increase in ribosomal protein expression in all 14 UPEC isolates, which was suggestive of bacteria undergoing rapid growth. These data strongly support the previous findings of [@bib8], which found a gene expression profile consistent with rapid growth in elderly patients with UTIs. Furthermore, while we did observe increased r-protein expression in exponentially growing UPEC cultured in LB, these transcripts were dramatically more abundant in the context of infection (human and mouse). Thus, the findings that UPEC maintain a conserved gene expression during UTI and grow faster in the host in comparison to in vitro conditions is consistent across multiple studies and patient cohorts ([@bib8]), and supports recent studies that have documented very rapid UPEC growth rate measured directly in patients ([@bib10]; [@bib15]).

Importantly, our analysis reveals how this growth rate can be achieved. We found that regardless of external environment,\~50% of total gene expression is allocated to the core genome, consisting of metabolic and replication machinery, which mediate bacterial growth potential. When the infection-specific transcriptome was compared to that of UPEC cultured to mid-exponential phase in urine, we observed that elevated levels of ribosomal transcripts correlated with decreased levels of metabolic gene expression. We propose that this reallocation of resources within the core genome drives the rapid growth rate of UPEC during infection.

This resource reallocation is equivalent to what has been described as the bacterial 'growth law'. Based on in vitro studies, the growth law proposes that increases in ribosomal gene expression occurs at the expense of a cell's metabolic gene expression ([@bib7]; [@bib41]). Our analysis of UPEC gene expression directly from patients is consistent with this hypothesis. In addition, regulatory network analysis revealed that multiple metabolic regulons exhibit decreased transcript levels in patients suggesting an actively regulated process. In contrast, synthesis of ribosomal RNA (rRNA) coordinates the expression of ribosomal proteins by a translational feedback regulation mechanism ([@bib22]; [@bib23]; [@bib38]). rRNA synthesis is proposed to be regulated by the competition of RNA polymerase between transcription of rRNA operons and that of other genes, with some studies suggesting that mid-log growing cells might require almost all RNA polymerase dedicated to rRNA synthesis ([@bib22]; [@bib23]). Thus, decreased metabolic gene expression could allow the cell to shift its allocation of RNA polymerase towards rRNA synthesis and as a result, ribosomal protein expression. Although we cannot exclude other mechanisms, we propose that the reallocation of RNA polymerase molecules from metabolic genes to rRNA and ribosomal protein genes is a common feature adopted by diverse UPEC to promote rapid growth during UTI.

Three recent studies have attempted to characterize UPEC gene expression in patients with UTIs ([@bib8]; [@bib19]; [@bib47]). These studies focused on the importance of virulence factor expression in specific strains and have demonstrated changes in gene expression between infection and in vitro cultures. It should be noted that all of these studies, as well as our own, were performed using bacterial RNA isolated from patient urine (that was immediately stabilized upon collection). As a result, we cannot exclude the possibility that gene expression of UPEC residing in the bladder may differ from UPEC isolated from patient urine. However, the fact remains that we and others ([@bib8]) report that patients with different histories of UTIs all harbored a population of actively dividing bacteria in a remarkably specific metabolic state, which we have also recapitulated in a mouse model of infection in this study.

These findings raise a number of interesting questions. Firstly, how is rapid growth rate beneficial to UPEC? For example, rapid growth rate could be necessary to avoid the hosts' innate immune response such as micturition or epithelial cell shedding. Additionally, how does this growth rate influence the tempo and mode of bacterial evolution, especially with regards to genomic integrity and the acquisition of antibiotic resistance? Finally, what are the external cues that launch the infection-specific transcriptional response? It has been noted previously that filtered urine lacks some proteins that are present in unfiltered urine ([@bib18]), thus it would be interesting to see if supplementation of filtered urine with specific proteins/metabolites could recapitulate in vivo phenotype. While our study was not designed to identify infection-specific metabolites, our regulatory network analysis suggests that multiple environmental cues might reinforce the suppression of metabolic gene expression. We suggest that identifying and targeting these environmental cues is a promising approach to limit UPEC growth during UTI and gain the upper hand on this pathogen.

Materials and methods {#s4}
=====================

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                    Designation                                  Source or\      Identifiers    Additional information
  (species) or\                                                                                 reference                      
  resource                                                                                                                     
  ------------------------------------------------ -------------------------------------------- --------------- -------------- --------------------------------------------------------------
  Strain, strain background\                       Uropathogenic *Escherichia coli* HM01        This study                     Strain isolation described in **Study Design** section below
  (*Escherichia coli*)                                                                                                         

  Strain, strain background\                       Uropathogenic *Escherichia coli* HM03        This study                     Strain isolation described in **Study Design** section below
  (*Escherichia coli*)                                                                                                         

  Strain, strain background\                       Uropathogenic *Escherichia coli* HM06        This study                     Strain isolation described in **Study Design** section below
  (*Escherichia coli*)                                                                                                         

  Strain, strain background\                       Uropathogenic *Escherichia coli* HM07        This study                     Strain isolation described in **Study Design** section below
  (*Escherichia coli*)                                                                                                         

  Strain, strain background\                       Uropathogenic *Escherichia coli* HM14        This study                     Strain isolation described in **Study Design** section below
  (*Escherichia coli*)                                                                                                         

  Strain, strain background\                       Uropathogenic *Escherichia coli* HM17        This study                     Strain isolation described in **Study Design** section below
  (*Escherichia coli*)                                                                                                         

  Strain, strain background (*Escherichia coli*)   Uropathogenic *Escherichia coli* HM43        This study                     Strain isolation described in **Study Design** section below

  Strain, strain background (*Escherichia coli*)   Uropathogenic *Escherichia coli* HM54        This study                     Strain isolation described in **Study Design** section below

  Strain, strain background (*Escherichia coli*)   Uropathogenic *Escherichia coli* HM56        This study                     Strain isolation described in **Study Design** section below

  Strain, strain background (*Escherichia coli*)   Uropathogenic *Escherichia coli* HM57        This study                     Strain isolation described in **Study Design** section below

  Strain, strain background (*Escherichia coli*)   Uropathogenic *Escherichia coli* HM60        This study                     Strain isolation described in **Study Design** section below

  Strain, strain background (*Escherichia coli*)   Uropathogenic *Escherichia coli* HM66        This study                     Strain isolation described in **Study Design** section below

  Strain, strain background (*Escherichia coli*)   Uropathogenic *Escherichia coli* HM68        This study                     Strain isolation described in **Study Design** section below

  Strain, strain background (*Escherichia coli*)   Uropathogenic *Escherichia coli* HM86        This study                     Strain isolation described in **Study Design** section below

  Strain, strain background (*Escherichia coli*)   Uropathogenic *Escherichia coli* HM26        ([@bib47])                     

  Strain, strain background (*Escherichia coli*)   Uropathogenic *Escherichia coli* HM27        ([@bib47])                     

  Strain, strain background (*Escherichia coli*)   Uropathogenic *Escherichia coli* HM46        ([@bib47])                     

  Strain, strain background (*Escherichia coli*)   Uropathogenic *Escherichia coli* HM65        ([@bib47])                     

  Strain, strain background (*Escherichia coli*)   Uropathogenic *Escherichia coli* HM69        ([@bib47])                     

  Strain, strain background (*Mus musculus*)       CBA/J                                                                       

  commercial assay or kit                          MICROBEnrich Kit                             Thermo Fisher   AM1901         

  commercial assay or kit                          RNeasy kit                                   Qiagen          74104          

  commercial assay or kit                          Turbo DNase kit                              Thermo Fisher   AM2238         

  commercial assay or kit                          iScript cDNA synthesis kit                   Bio Rad         1708890        

  commercial assay or kit                          ScriptSeq Complete Gold Kit (Epidemiology)   Illumina        Discontinued   

  commercial assay or kit                          ScriptSeq Complete Kit (Bacteria)            Illumina        Discontinued   

  commercial assay or kit                          PowerUP SYBR Green Master Mix                Bio Rad         A25779         

  commercial assay or kit                          Dynabeads mRNA DIRECT Purification kit       Thermo Fisher   61011          

  chemical compound, drug                          RNAprotect                                   Qiagen          76526          

  software, algorithm                              Trimmomatic                                  ([@bib9])       0.36           

  software, algorithm                              Bowtie2                                      ([@bib32])      2.3.4          

  software, algorithm                              samtools                                     ([@bib33])      1.5            

  software, algorithm                              HTseq                                        ([@bib5])       0.9.1          

  software, algorithm                              Get_homologues                               ([@bib12])      20170807       

  software, algorithm                              DESeq2                                       ([@bib35])      1.22.2         
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Study design {#s4-1}
------------

Sample collection was previously described ([@bib47]). Briefly, a total of 86 female participants, presenting with symptoms of lower UTI at the University of Michigan Health Service Clinic in Ann Arbor, MI in 2012, were enrolled in this study. The participants were compensated with a \$10 gift card to a popular retail store. Clean catch midstream urine samples from participants were immediately stabilized with two volumes of RNAprotect (Qiagen) to preserve the in vivo transcriptional profile. De-identified patient samples were assigned unique sample numbers and used in this study. Of the 86 participants, 38 were diagnosed with UPEC-associated UTIs ([@bib47]). Of these, 19 samples gave us sufficient RNA yield of satisfactory quality. Five were used for a pilot project ([@bib47]), the remaining 14 were used in this study.

Genome sequencing and assembly {#s4-2}
------------------------------

The genomic DNA from clinical strains of *E. coli* were isolated with CTAB/phenol-chloroform based protocol. Library preparation and sequencing were performed on PacBio RS system at University of Michigan Sequencing Core. De novo assemblies were performed with canu de novo assembler ([@bib30]) with all the parameters set to default mode and correction phase turned on. Finished genome assembly of reference strains (MG1655, CFT073, UTI89, EC958) were downloaded from NCBI and were converted to fastq reads using ArtificialFastqGenerator v1.0. Trimmomatic 0.36 ([@bib9]) was used for trimming adapter sequences. Variants were identified by (i) mapping filtered reads to reference genome sequence CFT073 (NC_004431) using the Burrows-Wheeler short-read aligner (bwa-0.7.17) ([@bib34]), (ii) discarding polymerase chain reaction duplicates with Picard (picard-tools-2.5.0), and (iii) calling variants with SAMtools (samtools-1.2,) ([@bib33]) and bcftools ([@bib33]). Variants were filtered from raw results using GATK' s (GenomeAnalysisTK-3.3--0 \[[@bib51]\]) VariantFiltration (QUAL,\>100; MQ,\>50; DP \>= 10 reads supporting variant; and FQ \<0.025). In addition, a custom python script was used to filter out single-nucleotide variants that were \<5 base pairs (bp) in proximity to indels. Positions that fell under the following regions were masked (substituted with N): (i) Phage and Repeat region of the reference genome (identified using Phaster and Nucmer; MUMmer3.23 \[[@bib31]\]) (ii) Low MQ and Low FQ regions (ii) base positions that didn't pass the hard filters (QUAL,\>100; DP \>= 10) were individually masked in each sample. Recombinant region identified by Gubbins 2.3.1 ([@bib13]) were filtered out and a maximum likelihood tree was constructed in RAxML 8.2.8 ([@bib46]) using a general-time reversible model of sequence evolution from the gubbins filtered alignment. Bootstrap analysis was performed with the number of bootstrap replicates determined using the bootstrap convergence test and the autoMRE convergence criteria (-N autoMRE). Bootstrap support values were overlaid on the best scoring tree identified during rapid bootstrap analysis (-f a).

Phylogroup, MLST, and serogroup typing {#s4-3}
--------------------------------------

Phylogroups were assigned using an in-house script based on the presence and absence of primer target sequences and typing scheme ([@bib11]). MLST schemes from pubmlst ([@bib28]) were downloaded using ARIBA's pubmlstget tool and sequence types were determined by running ARIBA ([@bib21]) against this pubmlst database. Serogroups were determined using SerotypeFinder ([@bib24]).

Bacterial culture conditions {#s4-4}
----------------------------

Human urine was pooled from four age-matched healthy female volunteers. Overnight cultures of clinical isolates were washed once in human urine, then 250 μl of overnight culture was added to 25 ml of filter-sterilized human urine and cultured statically at 37C for 2 hours. Six milliliters of this culture were stabilized with RNAprotect (Qiagen) and used for RNA purification.

Antibiotic resistance profiling {#s4-5}
-------------------------------

As described in [@bib47], identity and antibiotic resistance profiles of UPEC isolates were determined using a VITEK2 system (BioMerieux).

RNA isolation and sequencing {#s4-6}
----------------------------

RNA isolation protocol was previously described ([@bib47]). Briefly, samples were treated with proteinase K and total RNA was isolated using Qiagen RNAeasy minikit. Turbo DNase kit (Ambion) was used to remove contaminating DNA. Bacterial content of patient samples was enriched using MICROBEnrich kit (Ambion), which depletes RNA of eukaryotic mRNA and rRNA. Library preparation and sequencing was performed by University of Michigan sequencing core. ScriptSeq Complete Kit (Bacteria) library kit was used to both deplete samples of bacterial rRNA and to construct stranded cDNA libraries from the rRNA-depleted RNA ([Table 3](#table3){ref-type="table"}, [Table 4](#table4){ref-type="table"}). While the original in vitro samples submitted for sequencing were not treated with MICROBEnrich kit, we have since performed extensive testing with two different clinical UTI strains (HM86 and HM56) to show that treatment with the kit does not affect the measured gene expression ([Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}, [Supplementary file 1](#supp1){ref-type="supplementary-material"}). All samples were sequenced using Illumina HiSeq2500 (single end, 50 bp read length).

RT-PCR validation of MICROBEnrich-treated samples {#s4-7}
-------------------------------------------------

Clinical strains HM56 and HM86 were cultured overnight in LB broth at 37°C. The next morning, the culture was spun down, and the pellet washed once with PBS. Pooled filter-sterilized human urine was then inoculated with the washed bacteria at a ratio of 1:100 and incubated shaking at 37°C for five hours. Cultures were then treated with bacterial RNAprotect (Qiagen), pellets collected and stored at −80°C. The bacterial pellets were treated with both lysozyme and proteinase K, and then total RNA was extracted using the RNAeasy kit (Qiagen). Genomic DNA was removed using the Turbo DNA free kit (ThermoFisher). The extracted RNA was then halved. One half was treated using the MICROBEnrich kit (ThermoFisher), which should only remove eukaryotic mRNA and eukaryotic rRNA. The second half of the RNA remained untreated. Both the MICROBEnrich and untreated samples were reverse-transcribed into cDNA using the iScript cDNA synthesis kit (Biorad), with 1 μg RNA as template. Real-Time Quantitative Reverse Transcription PCR (qRT-PCR) was performed in a Quantstudio 3 PCR system (Applied Biosystem) in technical triplicate, using SYBR green (ThermoFisher). Samples were normalized to *gapA* transcript levels, by subtracting the Ct values of *gapA* from the Ct values of monitored genes. This value is reported as ΔCt.

Characterization of virulence factors' gene expression {#s4-8}
------------------------------------------------------

We compiled a literature search-based list of virulence factors belonging to different functional groups. Sequences for each virulence factor gene were extracted from reference UPEC genomes (either CFT073 or UTI89). Presence or absence of each virulence factor within clinical genomes was determined using BLAST (with percent identity ≥80% and percent coverage ≥90%, e-value ≤10^−6^). Hierarchical clustering of strains based on presence or absence of virulence factors was performed using Python's scipy.cluster.hierarchy.linkage function with default parameters. Heatmaps of virulence factors' gene expression in urine and in patients show normalized transcripts per million (TPMs) (same as for correlation analysis and PCA, see below).

RNAseq data processing {#s4-9}
----------------------

A custom bioinformatics pipeline was used for the analysis ([@bib44]; copy archived at <https://github.com/elifesciences-publications/rnaseq_analysis>). Raw fastq files were processed with Trimmomatic ([@bib9]) to remove adapter sequences and analyzed with FastQC to assess sequencing quality. Mapping was done with bowtie2 aligner ([@bib32]) using default parameters. Alignment details can be found in [Table 3](#table3){ref-type="table"} and [Table 4](#table4){ref-type="table"}. Read counts were calculated using HTseq htseq-count (union mode) ([@bib5]).

Quality control {#s4-10}
---------------

Since some of our clinical samples yielded lower numbers of bacterial reads than desired ([Table 3](#table3){ref-type="table"}), we performed a comprehensive quality assurance to determine if the sequencing depth of our clinical samples was sufficient for our analysis (see Saturation curves and Gene expression ranges analysis below, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}, [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). Overall, all patient samples except for HM66 passed quality control (see gene expression ranges analysis, [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). While we elected to keep all of the strains in our subsequent analysis, this observation explains why the patient HM66 sample appears as an outlier in [Figure 2](#fig2){ref-type="fig"}.

Saturation curves {#s4-11}
-----------------

We created saturation curves for each of our sequencing files to assess whether we have sufficient sequencing depth for downstream analysis. Each sequencing file was subsampled to various degrees and number of genes detected in those subsamples (y-axis) was graphed against number of reads in the subsample (x-axis). As expected, all of the in vitro samples reached saturation ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}, blue lines). Unfortunately, 6 out of our 14 samples did not reach saturation, which warranted us to investigate further (see Gene expression ranges analysis) [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}, red lines). Additionally, dropping the six samples that did not reach saturation from our analysis did not affect any of the results.

Core genome identification {#s4-12}
--------------------------

Core genome for 14 clinical isolates and MG1655 was determined using get_homologues ([@bib12]). We explored multiple parameter values for our analysis and their effect on final core genome, in the end we set the cut off of 90% of sequence identity and 50% sequence coverage (similar results were obtained when using different cutoffs). The intersection of three algorithms employed by get_homologues contained 2653 gene clusters.

Gene expression ranges analysis {#s4-13}
-------------------------------

Due to low sequencing depth of 6 of our isolates, we were worried we would not be able to detect genes expressed at low levels in those samples. To evaluate whether we were losing information about low-level expression, we compared a number of genes in the core genome that were expressed at different levels (1000 TPMS, 100 TPMS, 10 TPMS and 1 TPM) between clinical samples that reached saturation ([Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"}) and those that did not ([Figure 2---figure supplement 2B](#fig2s2){ref-type="fig"}). Only one of the clinical samples (HM66) seemed to lack genes expressed in the range of 1--10 TPMs. Thus, we conclude that all but one sample (HM66) had sufficient coverage for downstream analysis.

Pearson correlation coefficient calculation and PCA analysis {#s4-14}
------------------------------------------------------------

For PCA and correlation analysis, transcript per million (TPM) was calculated for each gene, TPM distribution was then normalized using inverse rank transformation. Pearson correlation and PCA was performed using python Python sklearn library. Jupyter notebooks used to generate the figures are available at <https://github.com/ASintsova/HUTI-RNAseq>.

Differential expression analysis {#s4-15}
--------------------------------

Differential expression analysis was performed using DESeq2 R package ([@bib35]). Genes with log2 fold change of greater than two or less than −2 and adjusted *p* value (Benjamini-Hochberg adjustment) of less than 0.05 were considered to be differentially expressed. DESeq2 normalized counts were used to generate [Figure 3](#fig3){ref-type="fig"} and [Figure 6](#fig6){ref-type="fig"}. Pathway analysis was performed using R package topGO ([@bib2]).

RNA sequencing of HM43 from the mouse model of UTI {#s4-16}
--------------------------------------------------

Forty CBA/J mice were infected using the ascending model of UTI as previously described ([@bib20]). Briefly, 40 six-week-old female mice were transurethrally inoculated with 10^8^ CFU of UPEC isolate HM43. 48 hr post infection urine was collected from each mouse directly into bacterial RNAprotect (Qiagen). All collected urine was pooled together and pelleted, and immediately placed in the −80°C freezer. This collection was repeated every 45 minutes five more times, resulting in six collected pellets consisting of bacterial and eukaryotic cells.

For in vitro controls, UPEC strain HM43 was cultured overnight in LB. The next morning, the culture was spun down, and the pellet washed twice with PBS. LB or pooled human urine was then inoculated with the washed bacteria at a ratio of 1:100 and incubated with shaking at 37°C for 3 hr. Cultures were then treated with bacterial RNAprotect (Qiagen), pellets collected and stored at −80°C.

All the pellets were treated with both lysozyme and proteinase K, and then total RNA was extracted using RNAeasy kit (Qiagen). Genomic DNA was removed using the Turbo DNA free kit (ThermoFisher). Eukaryotic mRNA was depleted using dynabeads covalently linked with oligo dT (ThermoFisher). The in vitro samples underwent the same treatment with dynabeads to reduce any potential biases this procedure might introduce to the downstream sequencing. The supernatant was collected from this treatment, and the RNA was concentrated and re-purified using RNA Clean and Concentrator kit (Zymo). Library preparation and sequencing was performed by University of Michigan sequencing core. The ScriptSeq Complete Gold Kit (Epidemiology) library kit was used to both deplete samples of bacterial and eukaryotic rRNA and to construct stranded cDNA libraries from the rRNA-depleted RNA. These were sequenced using Illumina HiSeq2500 (single end, 50 bp read length). RNAseq analysis was performed as described above, alignment statistics are shown in [Table 8](#table8){ref-type="table"} and [Table 9](#table9){ref-type="table"}.

Analysis of RNAseq data from [@bib47]. Sample collection and RNA isolation is described in [@bib47]. Briefly, RNA samples were treated with proteinase K and total RNA was isolated using Qiagen RNAeasy minikit. Turbo DNase kit (Ambion) was used to remove contaminating DNA. Bacterial content of patient samples was enriched using MICROBenrich kit (Ambion). The depleted RNA was used to generate sequencing libraries using the Ovation Prokaryotic RNA-Seq system (NuGen) and the Encore next-generation sequencing library system (NuGen). The libraries were sequenced using an Illumina HiSeq2000 (paired-end, 100 bp) by the Genome Resource Center at the Institute for Genome Sciences, University of Maryland, Baltimore, MD. RNAseq analysis was performed as described above, alignment statistics are shown in [Table 6](#table6){ref-type="table"} and [Table 7](#table7){ref-type="table"}.

Estimation of HM43 doubling time {#s4-17}
--------------------------------

For both LB and urine OD curves were performed using Bioscreen-C Automated Growth Curve Analysis System (Growth Curves USA) eight separate times. For each time point, the mean values of the eight replicates were used for doubling time estimation. The equation bellow was used to estimate doubling time during logarithmic growth in LB or urine, where DT is doubling time, C2 is final OD, C1 is initial OD, and $\mathrm{\Delta}t$ is time elapsed between when C2 and C1 were taken.$$DT = \frac{\mathrm{\Delta}t*log2}{log\left( {C2} \right) - log\left( C1 \right)}$$

DT was calculated for every two measurements taken between 30 and 180 min and mean of these values is reported.

Regulon analysis {#s4-18}
----------------

Regulon gene sets were extracted from RegulonDB 9.4 ([@bib17]) using custom Python scripts (available <https://github.com/ASintsova/HUTI-RNAseq>). Gene set enrichment analysis was performed using Python GSEAPY library.

Data access {#s4-19}
-----------

Jupyter notebooks as well as all the data used to generate the figures in this paper are available on github: <https://github.com/ASintsova/HUTI-RNAseq>.
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\[Editors' note: a previous version of this study was rejected after peer review, but the authors submitted for reconsideration. The first decision letter after peer review is shown below.\]

Thank you for submitting your work entitled \"Genetically diverse *Escherichia coli* adopt a common transcriptional program in patients with urinary tract infections\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and a Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Alexander Westermann (Reviewer \#2).

Our decision has been reached after consultation between the reviewers. Based on these discussions and the individual reviews below, we regret to inform you that your work will not be considered further for publication in *eLife*. All reviewers agreed on the importance of your work on characterising the transcriptional program of strains directly from patients. However, they raised serious technical questions with respect to the different processing of the RNA samples from patients, mice and in vitro, and potential confounding factors that cannot be eliminated without extensive new experiments. If you wished to address all the reviewers\' concerns, we would be willing to assess the suitability for publication of an extensively revised version of this manuscript.

Reviewer \#1:

This manuscript continues a large body of work by Mobley and co-workers to define a UPEC virulence genotype during human UTI. The authors use RNAseq to characterise a transcriptional program shared by a genetically diverse group of 14 UPEC strains harvested directly from the urine of infected patients. This revealed a signature defining upregulation of genes involved in translation, and demonstrating that UPEC grow rapidly during human UTI.

A major strength of this work is the transcriptome analysis of UPEC growth during human UTI, and comparison of this to growth in vitro and growth in the mouse model of UTI. The conserved transcriptional signature of the core genome during human UTI led to the important discovery that reprogramming occurs, and results in the allocation of cellular resources to support rapid growth during human UTI. It was comforting to see a conserved profile of transcription in humans and mice, an important finding that will be of great value to the field. In a broader context, this work provides new insight into UPEC adaptation to the human urinary tract. The transcriptional program that defines rapid growth during human UTI provides a framework to design novel therapeutics that block this phenotype in UPEC, an urgent need in the context of rapidly increasing antibiotic resistance.

Overall, I have no substantive concerns regarding the data or major conclusions.

Reviewer \#2:

In the present study, Sintsova et al. profile expression of the core genome of 14 UPEC isolates right upon their collection from UTI patients and compare it with the corresponding bacterial transcriptome patterns when grown in vitro. In doing so, the authors identify a conserved expression pattern shared among all isolates, which is associated with an increased expression of mRNAs encoding ribosomal proteins and a reduced expression of metabolic genes in the in vivo isolates compared to the in vitro cultures. Based on this finding, the authors conclude that in vivo UPEC reallocates its resources to increase proliferation at the expense of metabolic activity, and consequently, that bacterial growth may be enhanced in the patient\'s bladder as compared to in vitro conditions. This would imply that one or several elusive host factors (present in the bladder but absent from the sterile-filtered urine) would enhance UPEC growth.

My major concern is that the study lacks enough data to support this hypothesis. The growth rate is deduced from the number of sequencing reads that map to genes for ribosomal proteins. This measure happens to fit with the growth behavior in vitro, when the authors compare UPEC replication in LB and sterile urine. However, this does not necessarily mean that the same applies in vivo. Given that this is their major finding, the authors may want to further support this speculation by in vivo data, e.g. by determining CFU counts in their mouse model over time of infection. Also, what would speak against their hypothesis is that genes for other cellular functions required for growth (such as DNA replication, cell division, etc.) appear not to be differentially expressed in vivo vs. in vitro.

Also with respect to the generation and analysis of RNAseq data, I have some comments:

-- It remains unclear if the authors sequenced bacterial total RNA or rRNA-depleted RNA. The MICROBEnrich kit used, depletes polyadenylated transcripts (eukaryotic mRNAs and certain lincRNAs) as well as eukaryotic rRNAs, but does not efficiently deplete bacterial rRNA. Also the Illumina ScriptSeq v2 kit per se, does not deplete ribosomal transcripts. Therefore, it appears unclear why the authors state that \"... rRNA-depleted stranded cDNA libraries...\" were constructed. By the way, if indeed not actively depleted, reads mapping to bacterial rRNAs should also be increased in the in vivo samples (as are reads mapping to ribosomal proteins). In general, plots or tables that inform about RNA class distributions (% reads mapping to mRNAs, rRNAs, tRNAs, etc.) in the individual samples would be helpful.

-- Why didn\'t the authors include published datasets in their analysis? This would seem particularly obvious for the data derived from their own previous (pilot) study (Subashchandrabose et al., 2014) that was based on 5 samples taken together with the 14 samples analyzed here.

Reviewer \#3:

The manuscript \"Genetically diverse uropathogenic *Escherichia coli* adopt a common transcriptional program in patients with urinary tract infections\", by Sintsova et al., presents an RNAseq-driven analysis of UPEC gene expression from 14 UTI patients. The main experiment is to compare the expression of the bacteria directly isolated from the patients to the expression of the bacteria after growth in filter-sterilized, pooled human urine in vitro. The primary result is that bacteria isolated from the urine of patients have high expression of genes encoding proteins involved in DNA and protein synthesis: ribosomal proteins, rRNA and tRNA modification proteins, purine and pyrimidine metabolism.

The primary result was examined with a few analyses on the patient vs. in vitro urine expression. The analysis was split early between virulence genes/accessory genes and \"core\" genes that are present in all the strains. The analysis focused relatively quickly on the core genes, which included all the DNA and protein synthesis genes noted above. Further analysis of the core genes resulted in a few other general features that differentiated patient (infection) from in vitro growth: downregulation of amino acid biosynthesis, downregulation of sugar metabolism, downregulation of most sugar transporters, and upregulation of amino acid transporters.

An important set of validation experiments was then done with one strain, HM43, which was grown in LB (considered a \"rich\" lab media), a new batch of filter-sterilized urine, and multiple urine samples from mice that had been infected in their bladders with HM43. Using% of reads mapping to genes encoding ribosomal proteins and to genes encoding catabolic enzymes showed that the in vivo mouse infection samples again had a high proportion of ribosomal reads and low catabolic reads, more similar to the human patient expression data and not matched by the LB-grown bacteria. This last comparison was the main test the effect of a faster growth rate per se.

The authors then conclude that there is an infection-specific transcriptional program which is dedicated to high growth rate in urine. They further noted that the downstream regulated genes for 22 transcriptional factors were differentially expressed between patient infections and in vitro urine growth, and speculate that some environmental cues may be sensed and thereby lead to the observed high expression of DNA and protein synthesis genes.

I have one primary technical question about the experimental design and a question about the context within the UTI field. First, the authors have had substantial experience with doing RNAseq from patient urines, and take care to attempt to minimize the time between urine sample collection and RNAProtect addition (to be applauded). Also, all samples according to the Materials and methods are also stored in RNAProtect. One remaining issue is that it states that the \"bacterial content of patient samples was enriched using MICROBEnrich kit\". This raises a potential confounding variable that seems reasonable for explaining a large scale consistent different between patient samples and in vitro urine samples. For the HM43 mouse experiment, it is stated that \"eukaryotic mRNA was depleted using dynabeads covalently linked with oligodT\". This would seem to leave the eukaryotic ribosomal RNA still in the sample, but sequencing and mapping statistics for this experiment (similar to Table 1 for the human samples) are not included to check on this. Therefore, I am wondering whether the in vivo mouse samples were also treated differently than the in vitro LB and urine samples. Regardless, the authors should clarify the methods particularly for whether the MICROBEnrich was used only on the patient samples and explicitly not on the in vitro urine samples, and also they should similarly provide a bit more detail on the processing of the mouse samples.

In addition, the primary result from this paper has largely been described before. Bielecki et al. (2014) performed RNAseq on 21 strains from human UTI patients, 4 of which were subsequently grown in LB for to get an in vitro RNAseq data set; also of note these authors used MICROBEnrich for host RNA removal on the human patient samples, and they did rRNA depletion with a MICROBExpress kit for the in vitro samples. I suggest that the authors more explicitly acknowledge this previous work and the general observations that have already been made, which will help them to either better differentiate their current study or strengthen the overall result shared by the two papers by providing additional validating data.

\[Editors' note: what now follows is the decision letter after the authors submitted for further consideration.\]

Thank you for submitting your article \"Genetically diverse uropathogenic *Escherichia coli* adopt a common transcriptional program in patients with UTIs\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Neil Ferguson as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Alexander Westermann (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

The work presented here is a revised version of a previous submission. The original paper was deemed very interesting by reviewers, who however had raised several key issues, notably potential confounding of results due to differences in in vitro vs. in vivo RNA isolation/processing in the lab. The reviewers now agree that you have provided substantial new data to address these concerns and would be willing to consider this manuscript positively for publication. However, there are a list of points that should be addressed before this could be considered.

Essential revisions:

1\) Could you explain how you selected the extra dataset provided in Figure 1---figure supplement 5 that suggests that MICROBEnrich has little effect on bacterial gene expression? Importantly, were these some of the genes that showed differential expression between the in vivo and in vitro samples? It is essential to include, if not already tested, at least some of the r-protein-encoding mRNAs in this analysis given their importance in the study.

2\) Table 3: Only a small percentage of the reads from the in vivo samples map to the UPEC genome. Could you explain what the remainder of the reads might be derived from? Would they map to the host genome (thus indicating that bacterial enrichment is rather low-efficient), or is there any evidence that some of those non-UPEC reads might be derived from other causative agents of UTI?

10.7554/eLife.49748.040

Author response

\[Editors' note: the author responses to the first round of peer review follow.\]

> Reviewer \#2:
>
> \[...\] My major concern is that the study lacks enough data to support this hypothesis. The growth rate is deduced from the number of sequencing reads that map to genes for ribosomal proteins. This measure happens to fit with the growth behavior in vitro, when the authors compare UPEC replication in LB and sterile urine. However, this does not necessarily mean that the same applies in vivo. Given that this is their major finding, the authors may want to further support this speculation by in vivo data, e.g. by determining CFU counts in their mouse model over time of infection. Also, what would speak against their hypothesis is that genes for other cellular functions required for growth (such as DNA replication, cell division, etc.) appear not to be differentially expressed in vivo vs. in vitro.

We appreciate the reviewers concerns and apologize for lack of clarity in our discussion of data on growth rate:

1\) As mentioned by the reviewer, levels of ribosomes/rRNA are known to be closely correlated with growth rate under many different experimental conditions (Basan, 2018; Basan et al., 2015; Molenaar et al., 2009; Scott et al., 2010; Scott and Hwa, 2011; You et al., 2013), and there is no reason to believe that this would not also hold true in an in vivosetting. Additionally, while, in the past, we have measured CFUs during infection, bacterial load cannot be used as a proxy for growth rate, as it will be affected by multiple factors besides bacterial growth rate (such as bacterial clearance by the immune response to the infection).

2\) We apologize that this was not clear from our text, but in fact we do show that other genes required for growth are upregulated during infection (Figure 3B, subsection "UPEC show increased expression of replication and translation machinery during UTI", first paragraph). In addition to genes mentioned in Figure 3, there are other genes required for growth that are listed in Figure 3---source data 1, such as *fis, dnaG* (DNA replication), *dbpA* (ribosome biogenesis)*, mrcA,* and *mrdA* (peptidoglycan biosynthesis). Additionally, while there are sure to be other genes/proteins that are required for growth that were not significantly upregulated during infection, they might be regulated at a translational/post-translational level, and thus would not be changed in their expression.

3\) Our conclusions about rapid growth rate are not only based on the gene expression profile observed in this study, but are also supported by previous studies that attempt to directly measure UPEC growth rate in patients with UTIs (Burnham et al., 2018; Forsyth et al., 2018). We have tried to make this clear throughout the manuscript (specifically in the last paragraph of the Introduction, the first paragraph of the subsection "UPEC show increased expression of replication and translation machinery during UTI" and in the third paragraph of the Discussion). In this study we show how this rapid growth rate can result from repartitioning of the bacterial transcriptome that is observed both during mouse and human UTI.

> Also with respect to the generation and analysis of RNAseq data, I have some comments:
>
> -- It remains unclear if the authors sequenced bacterial total RNA or rRNA-depleted RNA. The MICROBEnrich kit used, depletes polyadenylated transcripts (eukaryotic mRNAs and certain lincRNAs) as well as eukaryotic rRNAs, but does not efficiently deplete bacterial rRNA. Also the Illumina ScriptSeq v2 kit per se, does not deplete ribosomal transcripts. Therefore, it appears unclear why the authors state that \"... rRNA-depleted stranded cDNA libraries...\" were constructed. By the way, if indeed not actively depleted, reads mapping to bacterial rRNAs should also be increased in the in vivo samples (as are reads mapping to ribosomal proteins). In general, plots or tables that inform about RNA class distributions (% reads mapping to mRNAs, rRNAs, tRNAs, etc.) in the individual samples would be helpful.

We apologize for the lack of clarity and omission of RNA class distribution data. We have revised our Materials and methods section (subsection "RNA isolation and sequencing") and added Tables 3 and 4 to address this point. These tables show clear depletion of bacterial rRNA from our samples. Specifically, both eukaryotic and prokaryotic rRNA was depleted from the samples prior to sequencing. Bacterial content of patient samples was enriched using MICROBEnrich kit (Ambion), which depletes the sample of eukaryotic mRNA and rRNA. Library preparation and sequencing was performed by University of Michigan sequencing core. ScriptSeq Complete Kit (Bacteria) library kit (https://www.illumina.com/products/scriptseq-bacteria.html) was used to both deplete samples of bacterial rRNA and to construct stranded cDNA libraries from the rRNA-depleted RNA.

> -- Why didn\'t the authors include published datasets in their analysis? This would seem particularly obvious for the data derived from their own previous (pilot) study (Subashchandrabose et al., 2014) that was based on 5 samples taken together with the 14 samples analyzed here.

The samples from our pilot study were not analyzed alongside this study because the library preparation, sequencing and facility used in the pilot study were different. However, we appreciate this comment, which has also been brought up by reviewer \#3. We have now analyzed data from Subashchandrabose (2014) and show that it is consistent with our current study, i.e., increase intranscripts dedicated to r-protein production in the patient samples compared to LB or urine. These data have now been added as Figure 4---figure supplement 1 and are discussed in the last paragraph of the subsection "A shift in metabolic gene expression during UTI to optimize growth potential", and in the subsection "Analysis of RNAseq data from Subashchandrabose et al." One of the patient samples (HM26) had very few reads that mapped to the bacterial genome (Table 6, 7), which potentially explains the fact that this was the only patient sample that contained very few r-protein reads.

> Reviewer \#3:
>
> \[...\] I have one primary technical question about the experimental design and a question about the context within the UTI field. First, the authors have had substantial experience with doing RNAseq from patient urines, and take care to attempt to minimize the time between urine sample collection and RNAProtect addition (to be applauded). Also, all samples according to the Materials and methods are also stored in RNAProtect. One remaining issue is that it states that the \"bacterial content of patient samples was enriched using MICROBEnrich kit\". This raises a potential confounding variable that seems reasonable for explaining a large scale consistent different between patient samples and in vitro urine samples. For the HM43 mouse experiment, it is stated that \"eukaryotic mRNA was depleted using dynabeads covalently linked with oligodT\". This would seem to leave the eukaryotic ribosomal RNA still in the sample, but sequencing and mapping statistics for this experiment (similar to Table 1 for the human samples) are not included to check on this. Therefore, I am wondering whether the in vivo mouse samples were also treated differently than the in vitro LB and urine samples. Regardless, the authors should clarify the methods particularly for whether the MICROBEnrich was used only on the patient samples and explicitly not on the in vitro urine samples, and also they should similarly provide a bit more detail on the processing of the mouse samples.

1\) We sincerely apologize for the lack of clarity in our Materials and methods, as we did not state clearly whether eukaryotic/prokaryotic rRNA was depleted prior to RNA sequencing. We have expanded the Materials and methods section to clearly state that indeed both eukaryotic and prokaryotic rRNA was depleted from all of our samples sequenced in this study (subsection "RNA isolation and sequencing"), and provide additional tables showing numbers of reads that mapped to different types of RNA for each sample, for both clinical, in vitro and mouse samples (Tables 3, 4, 8, and 9).

2\) Additionally, we also failed to clearly explain that for the mouse study described in Figure 5 all samples (in vitroLB and urine cultures, as well as RNA isolated from mice with UTIs) were subjected to the same protocol (i.e., treatment with dynabeads covalently linked to oligo dT) to avoid any potential biases that could result from differential RNA processing. This clarification has now been added in the last paragraph of the subsection "RNA sequencing of HM43 from mouse model of UTI".

3\) The reviewer brought up a very important point suggesting that treatment of patient samples with MICROBEnrich could result in differential gene expression program we observed in the study. We want to point out that if treatment with MICROBEnrich affected the measurement of gene expression or RNA pool composition, we would expect to see large-scale global difference in gene expression, when in fact less than 500 genes were differentially expressed between the two conditions and were enriched in specific biological processes. However, we have taken this concern very seriously and provide five separate lines of evidence that the gene expression pattern observed in patient population is not due to an RNA processing step. These are summarized above, and are further elucidated below:

\- We have performed an extensive RT-PCR study to show that treatment with MICROBEnrich does not change the levels of gene expression in multiple UPEC strains cultured in urine. Specifically, we isolated RNA from urine cultures of HM86 and HM56, split each of the samples in half, where one half went through MICROBEnrich treatment, and the other was left untreated. We then measured gene expression for a panel of 10 different genes for both treated and untreated samples by RT-PCR and found no differences in gene expression between any of them. This was done in three biological replicates for HM86, and two biological replicates for HM56. This provides strong evidence that treatment with MICROBEnrich alone does not affect measurement of gene expression. These experiments are now explained in the Materials and methods subsection "RT-PCR validation of MICROBEnrich-treated samples" and presented in Figure 1---figure supplement 5, Table 10, and Supplementary file 1.

\- As discussed above, for the mouse UTI experiments, in vitroand in vivo RNA samples were treated exactly the same (yet differently from the original urine and patient samples). Nevertheless, the gene expression during mouse UTI highly resembles that of human UTI. This excludes the possibility of our results being attributable to MICROBEnrich.

\- In the revised Figure 1, we take a closer look at expression of genes that we expect to be similarly highly expressed in urine and patients (i.e., iron acquisition genes). As expected, we see a similar pattern of expression for a number of different virulence factors between in vitroand patient samples, which argues against a MICROBEnrich treatment having an effect on measured gene expression. This data is now presented in Figure 1B and Figure 1---figure supplement 3 and is described in the Results subsection "Virulence factor expression is not specific to infection".

\- One of the main conclusions of the paper (i.e., conserved gene expression program during UTI) does not rely on the comparison between in vitroand patient samples, and therefore the difference in treatment between these two sample groups would have minimal impact on our stated results. In fact, we first observed the conserved gene expression program when we compared gene expression of core genome and accessory genome between patients and observed that the core gene expression is more conserved. We apologize for omitting these data from the original manuscript, it is now included in Figure 2A and 2B and is discussed in the first paragraph of the subsection "The UPEC core genome exhibits a common gene expression program during clinical Infection".

\- Finally, we believe our original manuscript did not stress enough the importance of previous work on UPEC growth rate during infection. Specifically, Bielecki et al.(2014) have also observed a gene expression pattern consistent with fast growth in patients with UTIs. In addition, two other studies attempt to directly measure UPEC growth rate in patients with UTI and find it to be consistently fast \[(Burnham et al., 2018; Forsyth et al., 2018), the latter from our lab\]. The fact that multiple studies across different patient cohorts came to similar conclusions argues against our study being affected by differential MICROBEnrich treatment. We have revised the manuscript to highlight the previous work done by us and others throughout the Results and Discussion. Specifically, the following was modified: Introduction, last paragraph; subsection "UPEC show increased expression of replication and translation machinery during UTI", first paragraph; Discussion, third and sixth paragraphs.

> In addition, the primary result from this paper has largely been described before. Bielecki et al. (2014) performed RNAseq on 21 strains from human UTI patients, 4 of which were subsequently grown in LB for to get an in vitro RNAseq data set; also of note these authors used MICROBEnrich for host RNA removal on the human patient samples, and they did rRNA depletion with a MICROBExpress kit for the in vitro samples. I suggest that the authors more explicitly acknowledge this previous work and the general observations that have already been made, which will help them to either better differentiate their current study or strengthen the overall result shared by the two papers by providing additional validating data.

As discussed above, we are aware of the importance of the study described here, and it was not our intention to discount it in any way. In fact, we think that the fact that the two studies are in close agreement, despite studying different patient cohorts, is remarkable and significantly strengthens the conclusions of both studies. We have revised the text of the manuscript to more explicitly acknowledge this work, specifically the following was modified: Introduction, last paragraph; subsection "UPEC show increased expression of replication and translation machinery during UTI", first paragraph; Discussion, third and sixth paragraphs. We also want to emphasize that the purpose of our study was also to build on these findings and provide a mechanistic insight into how this growth rate could potentially be achieved. Specifically, we show how differential transcriptome partitioning can facilitate the rapid growth. Moreover, we recapitulate our observations in the mouse model of UTI and characterize *E. coli* regulatory network that is behind the transcriptome partitioning observed during human UTI.

> \[Editors\' note: the author responses to the re-review follow.\]
>
> Essential revisions:
>
> 1\) Could you explain how you selected the extra dataset provided in Figure 1---figure supplement 5 that suggests that MICROBEnrich has little effect on bacterial gene expression? Importantly, were these some of the genes that showed differential expression between the in vivo and in vitro samples? It is essential to include, if not already tested, at least some of the r-protein-encoding mRNAs in this analysis given their importance in the study.

For the original panel, we selected genes that have previously been shown to be important for UPEC infections. However, they were not differentially expressed between in vivoand in vitroconditions. We have now extended this panel by including data for five more genes, 2 of which (*nanM* and *malK*) were downregulated under in vivo conditions, and 3 of which (ribosomal protein genes *rpoA, rplA, rpsA*) were upregulated in vivo. As is shown in Supplementary file 1, MICROBEnrich treatment did not affect measurements of gene expression for any of the genes in the panel.

> 2\) Table 3: Only a small percentage of the reads from the in vivo samples map to the UPEC genome. Could you explain what the remainder of the reads might be derived from? Would they map to the host genome (thus indicating that bacterial enrichment is rather low-efficient), or is there any evidence that some of those non-UPEC reads might be derived from other causative agents of UTI?

The majority of the reads from those samples do indeed map to the host genome. Moreover, none of the patients in this study had polymicrobial infections. While the enrichment was not perfect, in our hands, it does significantly increase the amount of bacterial RNA in our samples.
